

Juan Carlos GarcÃ-a-Pagan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1932085/publications.pdf>

Version: 2024-02-01

392
papers

38,702
citations

1463

107
h-index

3579

181
g-index

412
all docs

412
docs citations

412
times ranked

15287
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding. <i>New England Journal of Medicine</i> , 2010, 362, 2370-2379.	27.0	1,075
2	Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis. <i>New England Journal of Medicine</i> , 2005, 353, 2254-2261.	27.0	952
3	Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis. <i>Gastroenterology</i> , 2007, 133, 481-488.	1.3	926
4	Baveno VII “Renewing consensus in portal hypertension. <i>Journal of Hepatology</i> , 2022, 76, 959-974.	3.7	890
5	Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure. <i>Gastroenterology</i> , 1996, 111, 1018-1022.	1.3	838
6	The clinical use of HVPG measurements in chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 573-582.	17.8	576
7	Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. <i>Lancet, The</i> , 1995, 346, 1056-1059.	13.7	569
8	Improved clinical outcome using polytetrafluoroethylene-coated stents for tips: Results of a randomized study. <i>Gastroenterology</i> , 2004, 126, 469-475.	1.3	468
9	Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. <i>Hepatology</i> , 2010, 51, 210-218.	7.3	458
10	Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. <i>Hepatology</i> , 2003, 37, 902-908.	7.3	456
11	Budd-Chiari syndrome: a review by an expert panel. <i>Journal of Hepatology</i> , 2003, 38, 364-371.	3.7	446
12	Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients With Compensated Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 102-111.e1.	1.3	437
13	Prognostic value of early measurements of portal pressure in acute variceal bleeding. <i>Gastroenterology</i> , 1999, 117, 626-631.	1.3	435
14	Hepatic Vein Pressure Gradient Reduction and Prevention of Variceal Bleeding in Cirrhosis: A Systematic Review. <i>Gastroenterology</i> , 2006, 131, 1611-1624.	1.3	435
15	Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings. <i>Gastroenterology</i> , 1998, 114, 1296-1303.	1.3	431
16	Etiology, Management, and Outcome of the Budd-Chiari Syndrome. <i>Annals of Internal Medicine</i> , 2009, 151, 167.	3.9	422
17	Complications of cirrhosis. I. Portal hypertension. <i>Journal of Hepatology</i> , 2000, 32, 141-156.	3.7	416
18	Efficacy and Safety of Anticoagulation on Patients With Cirrhosis and Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 776-783.	4.4	407

#	ARTICLE	IF	CITATIONS
19	Prevention of variceal rebleeding. <i>Lancet</i> , The, 2003, 361, 952-954.	13.7	398
20	Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. <i>Hepatology</i> , 1998, 28, 416-422.	7.3	374
21	Simvastatin Lowers Portal Pressure in Patients With Cirrhosis and Portal Hypertension: A Randomized Controlled Trial. <i>Gastroenterology</i> , 2009, 136, 1651-1658.	1.3	372
22	A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2014, 146, 1231-1239.e6.	1.3	353
23	Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. <i>Journal of Hepatology</i> , 2009, 50, 923-928.	3.7	340
24	Efficacy of Antiviral Therapy on Hepatitis C Recurrence After Liver Transplantation: A Randomized Controlled Study. <i>Gastroenterology</i> , 2007, 132, 1746-1756.	1.3	332
25	TIPS for Budd-Chiari Syndrome: Long-Term Results and Prognostic Factors in 124 Patients. <i>Gastroenterology</i> , 2008, 135, 808-815.	1.3	319
26	The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. <i>Blood</i> , 2008, 111, 4922-4929.	1.4	319
27	Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 73, 366-413.	7.3	295
28	A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding. <i>Gastroenterology</i> , 2014, 146, 412-419.e3.	1.3	285
29	Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. <i>Journal of Hepatology</i> , 2008, 48, 229-236.	3.7	284
30	Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. <i>Hepatology</i> , 2006, 43, 492-499.	7.3	282
31	A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 2747-2756.	0.4	268
32	Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial. <i>Hepatology</i> , 2008, 47, 1604-1614.	7.3	266
33	Use of early-TIPS for high-risk variceal bleeding: Results of a post-RCT surveillance study. <i>Journal of Hepatology</i> , 2013, 58, 45-50.	3.7	259
34	Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. <i>Endoscopy</i> , 2016, 48, 939-948.	1.8	257
35	The management of portal hypertension: Rational basis, available treatments and future options. <i>Journal of Hepatology</i> , 2008, 48, S68-S92.	3.7	248
36	Idiopathic noncirrhotic portal hypertension. <i>Hepatology</i> , 2011, 54, 1071-1081.	7.3	248

#	ARTICLE	IF	CITATIONS
37	Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. <i>Hepatology</i> , 2011, 54, 555-561.	7.3	240
38	Propranolol Compared with Propranolol plus Isosorbide-5-Mononitrate for Portal Hypertension in Cirrhosis. <i>Annals of Internal Medicine</i> , 1991, 114, 869-873.	3.9	237
39	Good long-term outcome of Budd-Chiari syndrome with a step-wise management. <i>Hepatology</i> , 2013, 57, 1962-1968.	7.3	237
40	Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. <i>Gastroenterology</i> , 2004, 126, 886-894.	1.3	236
41	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <i>Gastroenterology</i> , 2016, 150, 1160-1170.e3.	1.3	232
42	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. <i>Hepatology</i> , 2015, 62, 762-772.	7.3	230
43	Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis. <i>American Journal of Gastroenterology</i> , 2006, 101, 506-512.	0.4	228
44	Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. <i>Hepatology</i> , 2017, 65, 1293-1305.	7.3	225
45	PATHOPHYSIOLOGY OF PORTAL HYPERTENSION. <i>Gastroenterology Clinics of North America</i> , 1992, 21, 1-14.	2.2	221
46	Functional aspects on the pathophysiology of portal hypertension in cirrhosis. <i>Journal of Hepatology</i> , 2012, 57, 458-461.	3.7	219
47	Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: A multicenter survey on safety and efficacy. <i>Hepatology</i> , 2013, 57, 2448-2457.	7.3	217
48	Incidence, Prevalence, and Clinical Significance of Abnormal Hematologic Indices in Compensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 689-695.	4.4	215
49	Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. <i>Gastroenterology</i> , 2017, 153, 1273-1283.e1.	1.3	210
50	Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. <i>Journal of Hepatology</i> , 2007, 46, 1040-1046.	3.7	203
51	Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2009, 136, 1639-1650.	1.3	197
52	Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. <i>Journal of Hepatology</i> , 2005, 43, 98-103.	3.7	196
53	TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial. <i>Hepatology</i> , 2002, 35, 385-392.	7.3	195
54	TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. <i>Hepatology</i> , 2002, 35, 132-139.	7.3	190

#	ARTICLE	IF	CITATIONS
55	Wedge hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. <i>Hepatology</i> , 1999, 30, 1393-1397.	7.3	186
56	Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. <i>Gastroenterology</i> , 2001, 120, 161-169.	1.3	186
57	Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. <i>Hepatology</i> , 1993, 17, 355-360.	7.3	183
58	Real-time shear-wave elastography: Applicability, reliability and accuracy for clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2015, 62, 1068-1075.	3.7	183
59	Measurement of Portal Pressure and Its Role in the Management of Chronic Liver Disease. <i>Seminars in Liver Disease</i> , 2006, 26, 348-362.	3.6	182
60	Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. <i>Hepatology</i> , 2010, 52, 2044-2052.	7.3	180
61	Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLD. <i>PLoS ONE</i> , 2012, 7, e32785.	2.5	180
62	The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial stellate cell deactivation induced by statins. <i>Journal of Hepatology</i> , 2013, 58, 98-103.	3.7	180
63	Hepatic endothelial dysfunction and abnormal angiogenesis: New targets in the treatment of portal hypertension. <i>Journal of Hepatology</i> , 2010, 53, 558-567.	3.7	178
64	Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. <i>Liver International</i> , 2017, 37, 694-699.	3.9	178
65	Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis. <i>Gastroenterology</i> , 2019, 157, 149-162.	1.3	178
66	Portal Hypertension-Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1412-1417.	4.4	175
67	Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. <i>Hepatology</i> , 2016, 63, 1957-1967.	7.3	174
68	Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. <i>Journal of Hepatology</i> , 2019, 70, 458-469.	3.7	173
69	Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. <i>Hepatology</i> , 1990, 11, 230-238.	7.3	172
70	Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. <i>Gut</i> , 2013, 62, 452-460.	12.1	167
71	Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. <i>Hepatology</i> , 2007, 46, 1208-1217.	7.3	166
72	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	1.3	162

#	ARTICLE	IF	CITATIONS
73	Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. <i>Gastroenterology</i> , 2001, 121, 382-388.	1.3	159
74	KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. <i>Gut</i> , 2015, 64, 1434-1443.	12.1	159
75	Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha ₁ -adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. <i>Hepatology</i> , 1999, 30, 79-83.	7.3	158
76	Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 2000, 31, 1061-1067.	7.3	158
77	Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT. <i>Hepatology</i> , 2003, 37, 1260-1266.	7.3	149
78	Porto-sinusoidal vascular disease: proposal and description of a novel entity. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 399-411.	8.1	149
79	Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. <i>Gastroenterology</i> , 1996, 111, 1300-1306.	1.3	148
80	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	7.3	144
81	Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension. <i>Hepatology</i> , 2016, 63, 197-206.	7.3	143
82	PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. <i>Hepatology</i> , 2004, 40, 1197-1202.	7.3	142
83	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. <i>Journal of Hepatology</i> , 2012, 56, 103-108.	3.7	142
84	Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , 2004, 41, 384-390.	3.7	141
85	Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. <i>Gut</i> , 2011, 60, 1133-1138.	12.1	141
86	Portal vein thrombosis: A predictable milestone in cirrhosis?. <i>Journal of Hepatology</i> , 2009, 51, 632-634.	3.7	136
87	Idiopathic portal hypertension: Natural history and long-term outcome. <i>Hepatology</i> , 2014, 59, 2276-2285.	7.3	132
88	Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2008, 103, 1159-1167.	0.4	131
89	Endoscopic band ligation in the treatment of portal hypertension. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 526-535.	1.7	130
90	Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. <i>Gastroenterology</i> , 1995, 108, 1487-1495.	1.3	127

#	ARTICLE	IF	CITATIONS
91	Management of Gastric Varices. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 919-928.e1.	4.4	127
92	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002, 36, 1367-1373.	7.3	121
93	Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability. <i>Hepatology</i> , 2008, 47, 1248-1256.	7.3	118
94	Hemodynamic effects of acute changes in intra-abdominal pressure in patients with cirrhosis. <i>Gastroenterology</i> , 1993, 104, 222-227.	1.3	117
95	Time profile of the haemodynamic effects of terlipressin in portal hypertension. <i>Journal of Hepatology</i> , 1997, 26, 621-627.	3.7	117
96	Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. <i>Gastroenterology</i> , 1997, 112, 1284-1289.	1.3	117
97	Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. <i>Journal of Hepatology</i> , 2013, 58, 904-910.	3.7	117
98	Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. <i>Journal of Hepatology</i> , 2009, 51, 279-287.	3.7	116
99	Extrahepatic Portal Vein Thrombosis. <i>Seminars in Liver Disease</i> , 2008, 28, 282-292.	3.6	115
100	Portal Hypertension and Gastrointestinal Bleeding. <i>Seminars in Liver Disease</i> , 2008, 28, 003-025.	3.6	114
101	Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. <i>Journal of Hepatology</i> , 2010, 52, 846-853.	3.7	114
102	Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. <i>Hepatology</i> , 2018, 67, 1683-1694.	7.3	114
103	Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. <i>Hepatology</i> , 2006, 43, 707-714.	7.3	113
104	Endothelial expression of transcription factor Kruppel-like factor 2 and its vasoprotective target genes in the normal and cirrhotic rat liver. <i>Gut</i> , 2011, 60, 517-524.	12.1	113
105	Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. <i>Digestive and Liver Disease</i> , 2012, 44, 855-860.	0.9	113
106	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002, 36, 1367-1373.	7.3	113
107	Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2010, 53, 273-282.	3.7	112
108	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. <i>Hepatology</i> , 2020, 71, 1023-1036.	7.3	112

#	ARTICLE	IF	CITATIONS
109	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	3.7	112
110	Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. <i>Hepatology</i> , 1994, 19, 1095-1099.	7.3	111
111	Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. <i>Hepatology</i> , 2008, 47, 153-159.	7.3	111
112	Animal models of portal hypertension. <i>World Journal of Gastroenterology</i> , 2006, 12, 6577.	3.3	110
113	Effect of Meal Ingestion on Liver Stiffness in Patients with Cirrhosis and Portal Hypertension. <i>PLoS ONE</i> , 2013, 8, e58742.	2.5	110
114	Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. <i>Gastroenterology</i> , 1998, 115, 116-123.	1.3	108
115	Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?. <i>Gut</i> , 2002, 50, 425-427.	12.1	108
116	Inflammation and portal hypertension – The undiscovered country. <i>Journal of Hepatology</i> , 2014, 61, 155-163.	3.7	107
117	Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 2006, 43, 485-491.	7.3	106
118	Impact of anticoagulation on upper gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. <i>Hepatology</i> , 2015, 62, 575-583.	7.3	105
119	Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. <i>Journal of Hepatology</i> , 2020, 73, 1415-1424.	3.7	104
120	The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis. <i>Hepatology</i> , 2006, 44, 44-52.	7.3	103
121	Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. <i>Journal of Hepatology</i> , 2007, 47, 220-227.	3.7	100
122	Nontumoral portal vein thrombosis in patients awaiting liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 352-365.	2.4	99
123	Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: Influence in nitric oxide biosynthesis. <i>Gastroenterology</i> , 1996, 110, 1529-1535.	1.3	98
124	Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. <i>Gut</i> , 2009, 58, 1144-1150.	12.1	98
125	Paroxysmal nocturnal hemoglobinuria in Budd-Chiari Syndrome: Findings from a cohort study. <i>Journal of Hepatology</i> , 2009, 51, 696-706.	3.7	98
126	Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. <i>Journal of Hepatology</i> , 2016, 64, 834-842.	3.7	97

#	ARTICLE	IF	CITATIONS
127	Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. <i>Gastroenterology</i> , 2018, 155, 1564-1577.	1.3	97
128	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	3.7	97
129	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2021, 160, 193-205.e10.	1.3	97
130	Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. <i>Journal of Hepatology</i> , 1990, 11, 189-195.	3.7	96
131	5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: A possible role of cysteinyl-leukotrienes. <i>Gastroenterology</i> , 2002, 122, 387-393.	1.3	96
132	Budd-Chiari Syndrome Secondary to Antiphospholipid Syndrome. <i>Medicine (United States)</i> , 2001, 80, 345-354.	1.0	95
133	Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. <i>Hepatology</i> , 2020, 71, 658-669.	7.3	95
134	Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive β -blockers. <i>Gastroenterology</i> , 2001, 121, 908-914.	1.3	94
135	Serum bilirubin and platelet count: A simple predictive model for survival in patients with refractory ascites treated by TIPS. <i>Journal of Hepatology</i> , 2011, 54, 901-907.	3.7	94
136	Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers. <i>Hepatology</i> , 2012, 55, 921-930.	7.3	94
137	Current knowledge and management of portal vein thrombosis in cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 442-453.	3.7	93
138	Influence of Pharmacological Agents on Portal Hemodynamics: Basis for Its Use in the Treatment of Portal Hypertension. <i>Seminars in Liver Disease</i> , 1999, 19, 427-438.	3.6	92
139	Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. <i>Hepatology</i> , 1995, 22, 753-758.	7.3	90
140	Glucagon hinders the effects of somatostatin on portal hypertension. <i>Gastroenterology</i> , 1991, 101, 1710-1715.	1.3	89
141	Portal cholangiopathy: radiological classification and natural history. <i>Gut</i> , 2011, 60, 853-860.	12.1	88
142	Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. <i>Hepatology</i> , 2013, 58, 1742-1756.	7.3	87
143	Idiopathic Portal Hypertension in Patients With HIV Infection Treated With Highly Active Antiretroviral Therapy. <i>American Journal of Gastroenterology</i> , 2009, 104, 1707-1714.	0.4	85
144	Pregnancy in women with known and treated Budd-Chiari syndrome: Maternal and fetal outcomes. <i>Journal of Hepatology</i> , 2009, 51, 47-54.	3.7	85

#	ARTICLE	IF	CITATIONS
145	Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. <i>Hepatology</i> , 2013, 57, 1172-1181.	7.3	84
146	Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury. <i>Journal of Hepatology</i> , 2017, 66, 86-94.	3.7	84
147	Circadian variations of portal pressure and variceal hemorrhage in patients with cirrhosis. <i>Hepatology</i> , 1994, 19, 595-601.	7.3	82
148	Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. <i>Hepatology</i> , 2017, 66, 1219-1231.	7.3	80
149	Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2019, 71, 175-199.	3.7	80
150	PATTERNS OF VASOREGULATORY GENE EXPRESSION IN THE LIVER RESPONSE TO ISCHEMIA/REPERFUSION AND ENDOTOXEMIA. <i>Shock</i> , 1999, 11, 175-179.	2.1	79
151	Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: Comparison with the effects on portal pressure. <i>Hepatology</i> , 1988, 8, 861-865.	7.3	78
152	Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. <i>Hepatology</i> , 2003, 37, 378-384.	7.3	78
153	Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. <i>Journal of Hepatology</i> , 2006, 44, 1033-1039.	3.7	76
154	Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical-hemodynamic correlation study. <i>Hepatology</i> , 2010, 51, 2108-2116.	7.3	74
155	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 313-327.e6.	4.4	74
156	PPAR α activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. <i>Journal of Hepatology</i> , 2012, 56, 1033-1039.	3.7	73
157	Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. <i>Hepatology</i> , 2016, 63, 1640-1650.	7.3	73
158	Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. <i>Journal of Hepatology</i> , 2021, 75, 1367-1376.	3.7	73
159	Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2015, 62, 72-74.	3.7	72
160	Where does TIPS fit in the management of patients with cirrhosis?. <i>JHEP Reports</i> , 2020, 2, 100122.	4.9	72
161	Reduction of variceal pressure by propranolol: Comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. <i>Hepatology</i> , 1993, 18, 1082-1089.	7.3	71
162	The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells. <i>Hepatology</i> , 2017, 65, 2031-2044.	7.3	71

#	ARTICLE	IF	CITATIONS
163	The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices. <i>Gastroenterology</i> , 1997, 112, 2012-2016.	1.3	70
164	Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis. <i>Hepatology</i> , 1998, 28, 677-682.	7.3	69
165	Current concepts on the pathophysiology of portal hypertension. <i>Annals of Hepatology</i> , 2007, 6, 28-36.	1.5	69
166	Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. <i>Hepatology</i> , 2016, 64, 224-231.	7.3	69
167	Endoscopic assessment of variceal volume and wall tension in cirrhotic patients: Effects of pharmacological therapy. <i>Gastroenterology</i> , 1997, 113, 1640-1646.	1.3	68
168	Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. <i>Journal of Hepatology</i> , 2003, 39, 515-521.	3.7	68
169	Serum Fibrosis Markers Identify Patients With Mild and Progressive Hepatitis C Recurrence After Liver Transplantation. <i>Gastroenterology</i> , 2010, 138, 147-158.e1.	1.3	68
170	Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. <i>FASEB Journal</i> , 2019, 33, 11595-11605.	0.5	68
171	Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: Long-term hemodynamic and renal effects. <i>Hepatology</i> , 1994, 20, 1502-1508.	7.3	67
172	A prospective randomized trial of heater probe thermocoagulation versus injection therapy in peptic ulcer hemorrhage. <i>Gastrointestinal Endoscopy</i> , 1996, 43, 117-120.	1.0	67
173	Sonography of Budd-Chiari Syndrome. <i>American Journal of Roentgenology</i> , 2006, 187, W33-W41.	2.2	67
174	Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. <i>Gut</i> , 2009, 58, 118-125.	12.1	67
175	Review article: the modern management of portal hypertension – primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 178-186.	3.7	66
176	Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites*1. <i>Hepatology</i> , 1994, 20, 30-33.	7.3	66
177	Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. <i>World Journal of Gastroenterology</i> , 2005, 11, 6858.	3.3	66
178	Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 288, G763-G770.	3.4	65
179	Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. <i>Liver Transplantation</i> , 2010, 16, 348-356.	2.4	65
180	Insulin resistance and liver microcirculation in a rat model of early NAFLD. <i>Journal of Hepatology</i> , 2011, 55, 1095-1102.	3.7	64

#	ARTICLE	IF	CITATIONS
181	Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. <i>Liver International</i> , 2014, 34, 16-25.	3.9	64
182	Imaging in clinical decision-making for portal vein thrombosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 308-316.	17.8	64
183	Sonography of the Caudate Vein: Value in Diagnosing Budd-Chiari Syndrome. <i>American Journal of Roentgenology</i> , 2003, 181, 1641-1645.	2.2	63
184	Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline “ Update 2021. <i>Endoscopy</i> , 2021, 53, 751-762.	1.8	63
185	Acute Variceal Bleeding. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012, 33, 46-54.	2.1	62
186	Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. <i>Journal of Hepatology</i> , 2008, 48, 61-67.	3.7	61
187	Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats. <i>Journal of Hepatology</i> , 2013, 58, 240-246.	3.7	61
188	The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. <i>Journal of Hepatology</i> , 2019, 71, 942-950.	3.7	61
189	Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. <i>Journal of Hepatology</i> , 2013, 58, 1140-1146.	3.7	60
190	Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1846-1853.e1.	4.4	60
191	Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. <i>Gastroenterology</i> , 1992, 102, 2114-2119.	1.3	59
192	Liver sinusoidal endothelial dysfunction after LPS administration: A role for inducible-nitric oxide synthase. <i>Journal of Hepatology</i> , 2014, 61, 1321-1327.	3.7	58
193	The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. <i>Hepatology</i> , 2015, 62, 1584-1592.	7.3	57
194	Portal hypertension in acute liver failure.. <i>Gut</i> , 1992, 33, 965-968.	12.1	55
195	Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites. <i>Hepatology</i> , 1994, 20, 30-33.	7.3	55
196	Increased Hepatic Resistance. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S131-S137.	2.2	55
197	Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 811-818.	3.7	55
198	Variceal and other portal hypertension related bleeding. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 649-664.	2.4	54

#	ARTICLE	IF	CITATIONS
199	Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies. <i>Scientific Reports</i> , 2017, 7, 3255.	3.3	53
200	NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats. <i>Gut</i> , 2007, 56, 560-564.	12.1	52
201	Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension. <i>Gastroenterology</i> , 2017, 152, 1358-1365.	1.3	51
202	Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 584-590.	4.7	50
203	Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. <i>Journal of Hepatology</i> , 2017, 67, 501-507.	3.7	50
204	Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy*1. <i>Hepatology</i> , 1993, 17, 213-218.	7.3	50
205	Utility of Color Doppler Ultrasonography Predicting TIPS Dysfunction. <i>American Journal of Gastroenterology</i> , 2005, 100, 2696-2701.	0.4	49
206	Endoscopic Cyanoacrylate Injection Versus Balloon-occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Bleeding: A Randomized Controlled Trial. <i>Hepatology</i> , 2021, 74, 2074-2084.	7.3	49
207	Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis. <i>Journal of Hepatology</i> , 1996, 24, 423-429.	3.7	46
208	Increasing intra-abdominal pressure increases pressure, volume, and wall tension in esophageal varices. <i>Hepatology</i> , 2002, 36, 936-940.	7.3	46
209	Noninvasive Diagnostics for Portal Hypertension: A Comprehensive Review. <i>Seminars in Liver Disease</i> , 2020, 40, 240-255.	3.6	46
210	Idiopathic Portal Hypertension. <i>Hepatology</i> , 2018, 68, 2413-2423.	7.3	45
211	Prevalence, features and predictive factors of liver nodules in Fontan surgery patients: The VALDIG Fonliver prospective cohort. <i>Journal of Hepatology</i> , 2020, 72, 702-710.	3.7	45
212	Effects of Propranolol on Arterial Oxygenation and Oxygen Transport to Tissues in Patients with Cirrhosis. <i>The American Review of Respiratory Disease</i> , 1990, 142, 306-310.	2.9	44
213	CO2 wedged hepatic venography in the evaluation of portal hypertension. <i>Gut</i> , 2000, 46, 856-860.	12.1	43
214	Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. <i>Blood</i> , 2010, 115, 388-395.	1.4	43
215	The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. <i>Blood</i> , 2011, 117, 3968-3973.	1.4	43
216	Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis. <i>Journal of Hepatology</i> , 2011, 55, 307-314.	3.7	43

#	ARTICLE	IF	CITATIONS
217	Hepatic fibrin-ring granulomas in a patient with hepatitis A. <i>Gastroenterology</i> , 1991, 100, 268-270.	1.3	42
218	Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats. <i>Liver International</i> , 2017, 37, 1002-1012.	3.9	42
219	Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. <i>Blood</i> , 2021, 137, 1233-1240.	1.4	42
220	Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. <i>Hepatology</i> , 1993, 17, 213-218.	7.3	41
221	NCX-1000, a Nitric Oxide-Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study. <i>American Journal of Gastroenterology</i> , 2010, 105, 1094-1101.	0.4	40
222	Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. <i>Journal of Hepatology</i> , 2011, 54, 660-665.	3.7	40
223	Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G301-G309.	3.4	40
224	Liver Stiffness by Transient Elastography to Detect Portal Sinusoidal Vascular Liver Disease With Portal Hypertension. <i>Hepatology</i> , 2021, 74, 364-378.	7.3	40
225	Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. <i>Journal of Hepatology</i> , 2002, 36, 356-361.	3.7	39
226	Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. <i>Hepatology</i> , 2006, 43, 27-33.	7.3	39
227	Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats. <i>Journal of Hepatology</i> , 2008, 49, 192-197.	3.7	39
228	Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis. <i>Haematologica</i> , 2015, 100, e226-e228.	3.5	39
229	Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients. <i>Journal of Hepatology</i> , 1998, 29, 789-795.	3.7	38
230	Transjugular Intrahepatic Portosystemic Shunt for Acute Variceal Bleeding. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 495-505.	2.2	38
231	Acute variceal bleeding: risk stratification and management (including TIPS). <i>Hepatology International</i> , 2018, 12, 81-90.	4.2	38
232	Hepatic Venous Pressure Gradient Response in Non-Selective Beta-Blocker Treatment—Is It Worth Measuring?. <i>Current Hepatology Reports</i> , 2019, 18, 174-186.	0.9	38
233	Ascites after liver transplantation. <i>Liver Transplantation</i> , 2000, 6, 157-162.	2.4	37
234	Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats. <i>Hepatology</i> , 2013, 58, 1424-1435.	7.3	37

#	ARTICLE	IF	CITATIONS
235	Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G1191-G1198.	3.4	36
236	Hypercoagulability in Patients With Chronic Noncirrhotic Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 72-78.	4.4	36
237	Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy. <i>Scientific Reports</i> , 2016, 6, 22107.	3.3	35
238	2D shear wave liver elastography by Aixplorer to detect portal hypertension in cirrhosis: An individual patient data meta-analysis. <i>Liver International</i> , 2020, 40, 1435-1446.	3.9	35
239	Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. <i>JHEP Reports</i> , 2021, 3, 100264.	4.9	35
240	ISCHEMIA/REPERFUSION INDUCES AN INCREASE IN THE HEPATIC PORTAL VASOCONSTRICTIVE RESPONSE TO ENDOTHELIN-1. <i>Shock</i> , 1999, 11, 325-329.	2.1	34
241	Hepatocyte microvesicle levels improve prediction of mortality in patients with cirrhosis. <i>Hepatology</i> , 2018, 68, 1508-1518.	7.3	33
242	Effects of ritanserin, a selective and specific 5 ₂ -serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. <i>Hepatology</i> , 1993, 18, 389-393.	7.3	32
243	Endotipsitis: an emerging prosthetic-related infection in patients with portal hypertension. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 49, 77-82.	1.8	32
244	Transjugular Liver Biopsy. <i>Clinics in Liver Disease</i> , 2014, 18, 767-778.	2.1	32
245	A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. <i>Hepatology</i> , 2020, 72, 1353-1365.	7.3	32
246	TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard-of-Care Therapy. <i>Hepatology</i> , 2021, 74, 2735-2744.	7.3	32
247	Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. <i>Hepatology</i> , 2006, 43, 34-41.	7.3	31
248	Portal Hypertension Secondary to Myelofibrosis: A Study of Three Cases. <i>American Journal of Gastroenterology</i> , 2005, 100, 2355-2358.	0.4	30
249	Refractory Acute Variceal Bleeding: What to Do Next?. <i>Clinics in Liver Disease</i> , 2010, 14, 297-305.	2.1	30
250	Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation. <i>Shock</i> , 2017, 47, 370-377.	2.1	30
251	Ageing Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease. , 2019, 10, 684.		30
252	Nitric oxide and portal hypertension. <i>Metabolic Brain Disease</i> , 2002, 17, 311-324.	2.9	29

#	ARTICLE	IF	CITATIONS
253	Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 2461-2470.	3.6	28
254	Metabolomics Discloses Potential Biomarkers for the Noninvasive Diagnosis of Idiopathic Portal Hypertension. <i>American Journal of Gastroenterology</i> , 2013, 108, 926-932.	0.4	28
255	Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 867-876.	3.4	28
256	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	3.7	28
257	Potential role of antioxidants in the treatment of portal hypertension. <i>Journal of Hepatology</i> , 2007, 46, 193-197.	3.7	27
258	Cardiovascular Risk Factors and Systemic Endothelial Function in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , 2013, 108, 75-82.	0.4	27
259	Lymphocyte β_2 -adrenoceptors and plasma catecholamines in patients with cirrhosis. <i>Gastroenterology</i> , 1992, 102, 2015-2023.	1.3	26
260	Patients Whose First Episode of Bleeding Occurs While Taking a β_2 -Blocker Have High Long-term Risks of Rebleeding and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 670-676.	4.4	26
261	Pregnancy in idiopathic non-cirrhotic portal hypertension: A multicentric study on maternal and fetal management and outcome. <i>Journal of Hepatology</i> , 2018, 69, 1242-1249.	3.7	26
262	Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 985-992.	0.4	25
263	Portal vein thrombosis. <i>Current Opinion in Organ Transplantation</i> , 2018, 23, 250-256.	1.6	25
264	Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. <i>Journal of Hepatology</i> , 2021, 74, 89-95.	3.7	25
265	Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics. <i>Scientific Reports</i> , 2021, 11, 3048.	3.3	25
266	Combination of Model for End-stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding. <i>Hepatology</i> , 2021, 74, 2085-2101.	7.3	25
267	Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis*1, *2. <i>Hepatology</i> , 1994, 19, 1095-1099.	7.3	25
268	Long-term effects of distal splenorenal shunt on hepatic hemodynamics and liver function in patients with cirrhosis: Importance of reversal of portal blood flow. <i>Hepatology</i> , 1992, 15, 616-622.	7.3	24
269	Ascites after liver transplantation. <i>Liver Transplantation</i> , 2000, 6, 157-162.	2.4	24
270	Insulin resistance in patients with cirrhosis and portal hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G1458-G1465.	3.4	23

#	ARTICLE	IF	CITATIONS
271	New approaches in the pharmacologic treatment of portal hypertension. <i>Journal of Hepatology</i> , 1993, 17, S41-S45.	3.7	22
272	Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction. <i>Gut</i> , 2003, 52, 130-133.	12.1	22
273	Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. <i>British Journal of Haematology</i> , 2004, 124, 329-335.	2.5	22
274	Role of gap junctions modulating hepatic vascular tone in cirrhosis. <i>Liver International</i> , 2014, 34, 859-868.	3.9	22
275	Impact of prior portosystemic shunt procedures on outcome of liver transplantation. <i>Surgery</i> , 2005, 137, 620-625.	1.9	21
276	A novel form of the human manganese superoxide dismutase protects rat and human livers undergoing ischaemia and reperfusion injury. <i>Clinical Science</i> , 2014, 127, 527-537.	4.3	20
277	Enfermedades vasculares del hígado. Guías Clínicas de la Sociedad Catalana de Digestología y de la Asociación Española para el Estudio del Hígado. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 538-580.	0.5	20
278	Management of the major complications of cirrhosis: Beyond guidelines. <i>Journal of Hepatology</i> , 2021, 75, S135-S146.	3.7	20
279	The Pathophysiology of Portal Vein Thrombosis in Cirrhosis: Getting Deeper into Virchow's Triad. <i>Journal of Clinical Medicine</i> , 2022, 11, 800.	2.4	20
280	Hepatic, splanchnic and systemic haemodynamic abnormalities in portal hypertension. <i>Bailliere's Clinical Gastroenterology</i> , 1992, 6, 425-436.	0.9	19
281	Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 533-541.	1.9	19
282	Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, G496-G502.	3.4	19
283	Nicardipine increases hepatic blood flow and the hepatic clearance of indocyanine green in patients with cirrhosis. <i>Journal of Hepatology</i> , 1994, 20, 792-796.	3.7	18
284	A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures. <i>Liver International</i> , 2015, 35, 695-703.	3.9	18
285	Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature. <i>Cancers</i> , 2021, 13, 2688.	3.7	18
286	Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. <i>Journal of Hepatology</i> , 2013, 59, 717-722.	3.7	17
287	Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis. <i>Liver International</i> , 2019, 39, 705-713.	3.9	17
288	Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. <i>Annals of Hematology</i> , 2020, 99, 791-798.	1.8	17

#	ARTICLE	IF	CITATIONS
289	Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd-Chiari patients. <i>Liver Transplantation</i> , 2001, 7, 649-651.	2.4	16
290	New Insights into the Pathogenesis, Risk Factors, and Treatment of Portal Vein Thrombosis in Patients with Cirrhosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 673-681.	2.7	16
291	Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. <i>Blood Advances</i> , 2022, 6, 4516-4523.	5.2	16
292	The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2075-2082.	3.8	16
293	Effects of molsidomine, a long acting venous dilator, on portal hypertension. <i>Journal of Hepatology</i> , 1991, 13, 179-186.	3.7	15
294	ASSESSMENT OF PORTAL HYPERTENSION IN HUMANS. <i>Clinics in Liver Disease</i> , 2001, 5, 575-589.	2.1	15
295	Metabolomics as a diagnostic tool for idiopathic non-cirrhotic portal hypertension. <i>Liver International</i> , 2016, 36, 1051-1058.	3.9	15
296	Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 521-532.	2.6	15
297	Hyperkinetic circulation and decreased sensitivity to vasoconstrictors following portacaval shunt in the rat. Effects of chronic nitric oxide inhibition. <i>Journal of Hepatology</i> , 1999, 31, 719-724.	3.7	13
298	A Specialized, Nurse-Run Titration Clinic: A Feasible Option for Optimizing β -Blockade in Non-Clinical Trial Patients. <i>American Journal of Gastroenterology</i> , 2010, 105, 1917-1921.	0.4	13
299	Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2011, 54, 908-914.	3.7	12
300	Unexpected disappearance of portal cavernoma on long-term anticoagulation. <i>Journal of Hepatology</i> , 2014, 61, 446-448.	3.7	12
301	Reply. <i>Hepatology</i> , 2019, 69, 1360-1361.	7.3	12
302	Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis. <i>Journal of Hepatology</i> , 1996, 24, 430-435.	3.7	11
303	Prognosis of acute variceal bleeding: Is being on beta-blockers an aggravating factor? A short-term survival analysis. <i>Hepatology</i> , 2015, 62, 1840-1846.	7.3	11
304	Abdominal Surgery in Patients With Idiopathic Noncirrhotic Portal Hypertension: A Multicenter Retrospective Study. <i>Hepatology</i> , 2019, 70, 911-924.	7.3	11
305	Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease. <i>Journal of Hepatology</i> , 2021, 75, 924-934.	3.7	11
306	Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: A case-control study. <i>Hepatology</i> , 2022, 76, 418-428.	7.3	11

#	ARTICLE	IF	CITATIONS
307	Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators (J Hepatol 1985; 1: 325-337). Journal of Hepatology, 2004, 40, 887-890.	3.7	10
308	Prevention of recurrent variceal bleeding. Digestive and Liver Disease, 2008, 40, 337-342.	0.9	10
309	Calculating Hepatic Venous Pressure Gradient: Feel Free to Stay Free. Journal of Vascular and Interventional Radiology, 2016, 27, 1138-1139.	0.5	10
310	Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. Gastroenterología Y Hepatología (English Edition), 2017, 40, 538-580.	0.1	10
311	Congenital antithrombin deficiency in patients with splanchnic vein thrombosis. Liver International, 2020, 40, 1168-1177.	3.9	10
312	Monitoring of HVPG during pharmacological therapy: Evidence in favor of the prognostic value of a 20% reduction. Hepatology, 2004, 39, 1746-1747.	7.3	9
313	Primary prophylaxis of esophageal variceal bleeding in cirrhosis. Gastroenterologie Clinique Et Biologique, 2008, 32, 532-540.	0.9	9
314	Stroke Volume Response to Liver Graft Reperfusion Stress in Cirrhotic Patients. World Journal of Surgery, 2014, 38, 927-935.	1.6	9
315	Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis*1. Hepatology, 1995, 22, 753-758.	7.3	8
316	Feasibility and Safety of Pancreatic Islet Transplantation in the Liver by Portal Vein Catheterization using the Transjugular Route. Transplantation, 2006, 81, 1220-1221.	1.0	8
317	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study. Liver Transplantation, 2013, 19, 450-456.	2.4	8
318	Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma. Annals of Surgery, 2015, 261, e105.	4.2	8
319	Trials and Tribulations: The Prevention of Variceal Rebleeding. Gastroenterology, 2015, 149, 528-531.	1.3	8
320	Role of JAK 2 Mutation Detection in Budd-Chiari Syndrome (BCS) and Portal Vein Thrombosis (PVT) Associated to MPD.. Blood, 2006, 108, 377-377.	1.4	8
321	Effects of end-to-side portacaval shunt and distal splenorenal shunt on systemic and pulmonary haemodynamics in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 1999, 14, 1112-1118.	2.8	7
322	Non-selective beta-blockers in the prevention of first variceal bleeding. Is there any definite alternative?. Journal of Hepatology, 2002, 37, 393-395.	3.7	7
323	Endoscopic Hemostasis in Acute Esophageal Variceal Bleeding. Gastroenterology Clinics of North America, 2014, 43, 795-806.	2.2	7
324	Autoimmune biomarkers in portal sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology. Liver International, 2021, 41, 2171-2178.	3.9	7

#	ARTICLE	IF	CITATIONS
325	Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double-blind hemodynamic investigation*1. <i>Hepatology</i> , 1995, 22, 106-111.	7.3	6
326	5 Pharmacological prevention of variceal bleeding. New developments. <i>Bailliere's Clinical Gastroenterology</i> , 1997, 11, 271-287.	0.9	6
327	Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension. <i>Journal of Hepatology</i> , 2006, 44, 1040-1045.	3.7	6
328	Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis. <i>Liver International</i> , 2008, 28, 566-573.	3.9	6
329	Idiopathic Noncirrhotic Portal Hypertension in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2010, 50, 127-128.	5.8	6
330	Fibrinogen γ and variation in fibrinogen gamma genes in the etiology of portal vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2013, 109, 558-560.	3.4	6
331	Treatment of Acute Variceal Bleeding in 2021-When to Use Transjugular Intrahepatic Portosystemic Shunts?. <i>Clinics in Liver Disease</i> , 2021, 25, 345-356.	2.1	6
332	The Interplay between Pathophysiological Pathways in Early-Onset Severe Preeclampsia Unveiled by Metabolomics. <i>Life</i> , 2022, 12, 86.	2.4	6
333	Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis*1. <i>Hepatology</i> , 1995, 21, 83-88.	7.3	5
334	Anticoagulation in cirrhosis: Ready to set or wait!. <i>Hepatology</i> , 2013, 58, 1175-1176.	7.3	5
335	Esophageal Stents for Acute Variceal Bleeding: Expanding the Possibilities. <i>Digestive Diseases and Sciences</i> , 2018, 63, 275-276.	2.3	5
336	Budd-Chiari syndrome with short-length stenosis: still room for the angioplasty and wait-and-see strategy. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 823.	8.1	5
337	Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 927-928.	3.7	5
338	Risk of non-tumoural portal vein thrombosis in patients with HCV-induced cirrhosis after sustained virological response. <i>Liver International</i> , 2021, 41, 2954-2964.	3.9	5
339	Proximal Splenic Artery Embolization to Treat Refractory Ascites in a Patient With Cirrhosis. <i>Hepatology</i> , 2021, 74, 3534-3538.	7.3	5
340	Effects of ritanserlin, a selective and specific 5 ₂ -serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. <i>Hepatology</i> , 1993, 18, 389-393.	7.3	5
341	Spermidine Supplementation Protects the Liver Endothelium from Liver Damage in Mice. <i>Nutrients</i> , 2021, 13, 3700.	4.1	5
342	Platelet cytosolic calcium concentration in patients with liver cirrhosis. <i>Journal of Hepatology</i> , 1997, 27, 824-829.	3.7	4

#	ARTICLE	IF	CITATIONS
343	Early use of TIPS in patients with cirrhosis and variceal bleeding. <i>Annals of Internal Medicine</i> , 2010, 153, JC5.	3.9	4
344	Management of an acute variceal bleeding episode. <i>Clinical Liver Disease</i> , 2012, 1, 151-154.	2.1	4
345	Portal Hypertension Reverses Following Successful Antiviral Treatment for HCV: Fact or Fiction?. <i>Current Hepatology Reports</i> , 2018, 17, 209-217.	0.9	4
346	Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension. <i>Frontiers in Physiology</i> , 2021, 12, 649668.	2.8	4
347	The Budd-Chiari Syndrome. <i>New England Journal of Medicine</i> , 2004, 350, 1906-1908.	27.0	3
348	Microparticles and Paracrine Signaling in Portal Hypertension: Crucial Conversations or Idle Chat?. <i>Gastroenterology</i> , 2012, 143, 22-25.	1.3	3
349	Obeticholic acid: A new light in the shadows treating portal hypertension?. <i>Hepatology</i> , 2014, 59, 2072-2073.	7.3	3
350	Thromboprophylaxis with heparin in hospitalized patients with cirrhosis: friend or foe. <i>Liver International</i> , 2014, 34, 971-973.	3.9	3
351	Predicting Heart Failure After TIPS: Still More Questions Than Answers. <i>Hepatology</i> , 2019, 70, 1889-1891.	7.3	3
352	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. <i>JHEP Reports</i> , 2021, 3, 100368.	4.9	3
353	Prevention of variceal rebleeding. <i>Lancet, The</i> , 2003, 361, 2245.	13.7	2
354	Lack of Correlation Between Preoperative and Intraoperative Liver Hemodynamics. <i>Transplantation</i> , 2014, 97, 116-121.	1.0	2
355	The anticoagulant efficacy of rivaroxaban may be attenuated in cirrhotic patients. <i>Liver International</i> , 2017, 37, 1252-1252.	3.9	2
356	Reply to: "Splenic artery aneurysms, portal hypertension and pregnancy". <i>Journal of Hepatology</i> , 2019, 70, 1026-1027.	3.7	2
357	Risk factors of poor prognosis in patients with pyrrolidine alkaloids induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt. <i>Hepatology International</i> , 2021, 15, 568-570.	4.2	2
358	Impact of lifestyle interventions targeting physical exercise and caloric intake on cirrhosis regression in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 321, G603-G616.	3.4	2
359	Noninvasive tests in the post-liver transplantation setting. <i>Liver Transplantation</i> , 2007, 13, 628-629.	2.4	1
360	An overview of current treatment methods for Budd-Chiari syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 147-157.	0.8	1

#	ARTICLE	IF	CITATIONS
361	Reply. Hepatology, 2016, 64, 321-322.	7.3	1
362	Risk of bleeding in cirrhotic patients treated with rivaroxaban. Liver International, 2017, 37, 1575-1576.	3.9	1
363	Portal Hypertensive Bleeding. , 2019, , 171-179.e3.		1
364	Budd-Chiari Syndrome: Anticoagulation, TIPS, or Transplant. Current Hepatology Reports, 2020, 19, 197-202.	0.9	1
365	A simple nomogram identifies patients with refractory ascites with worse outcome after transjugular intrahepatic portosystemic shunt. European Journal of Gastroenterology and Hepatology, 2021, 33, e587-e593.	1.6	1
366	Failure to control variceal bleeding: Definition matters. Journal of Hepatology, 2021, 74, 1491-1492.	3.7	1
367	Reply to: "The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites". JHEP Reports, 2021, 3, 100349.	4.9	1
368	What else we need. , 2004, , 349-360.		1
369	Is it necessary to endoscopically screen all patients with hepatitis C and advanced fibrosis for esophageal varices?. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 370-371.	1.7	0
370	Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension. Journal of Cellular and Molecular Medicine, 2012, 16, 2017-2021.	3.6	0
371	Reply. Clinical Gastroenterology and Hepatology, 2013, 11, 103-104.	4.4	0
372	Reply. Gastroenterology, 2013, 144, 1153-1154.	1.3	0
373	Can we identify failure to control acute variceal bleeding?. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 705-706.	17.8	0
374	EASL Recognition Award Recipient 2015. Journal of Hepatology, 2015, 63, 785-786.	3.7	0
375	Acute Variceal Bleeding. , 2015, , 93-101.		0
376	Early transjugular intrahepatic portosystemic shunt: When, how and in whom?. Gastroenterology (English Edition), 2016, 39, 472-476.	0.1	0
377	Reply. Hepatology, 2017, 65, 2121-2122.	7.3	0
378	Nonendoscopic management of acute esophageal variceal bleeding. Techniques in Gastrointestinal Endoscopy, 2017, 19, 79-83.	0.3	0

#	ARTICLE	IF	CITATIONS
379	Reply to: "Calreticulin mutations and their importance in Budd-Chiari syndrome" Journal of Hepatology, 2017, 67, 1112-1113.	3.7	0
380	Idiopathic Portal Hypertension (Portosinusoidal Disease). , 2018, , 301-308.		0
381	Reply. Gastroenterology, 2018, 154, 1551-1552.	1.3	0
382	Reply:. Hepatology, 2019, 70, 753-754.	7.3	0
383	Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?" Journal of Hepatology, 2020, 73, 977-979.	3.7	0
384	Reply to: Correspondence on "Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis" Journal of Hepatology, 2021, 74, 252-254.	3.7	0
385	Reply. Gastroenterology, 2021, 161, 372-373.	1.3	0
386	Letter to the Editor: Salvage TIPS in Patients With Cirrhosis With Variceal Bleeding: MELD, Lactates, and "À la Carte" Decision. Hepatology, 2021, 74, 3558-3559.	7.3	0
387	Reply to: Correspondence on "Predicting portal thrombosis in cirrosis: A prospective study of clinical, ultrasonographic and hemostatic factors" Journal of Hepatology, 2022, 76, 227-228.	3.7	0
388	Enhanced release of vasoconstrictors. , 2004, , 89-96.		0
389	The Treatment and Prevention of Variceal Bleeding. , 2011, , 477-500.		0
390	Budd-Chiari Syndrome. , 2011, , 197-211.		0
391	TIPS: Primary Therapy or Rescue in Treatment of Acute Variceal Hemorrhage. , 2014, , 163-169.		0
392	Budd-Chiari Syndrome: Hepatic Venous Outflow Tract Obstruction. , 2022, , 79-92.		0